Press Releases
At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Mar 4, 2016CEO Clarke to provide update on PULM business activities
Pulmatrix, Inc., (NASDAQ: PULM) will present a business update at the Cowen and Company 36th Annual Health Care Conference on Wednesday, March 9th at 11:20 am EST (8:20 am PST). A live webcast of...
-
Feb 16, 2016
Capsugel and Pulmatrix, Inc. ("Pulmatrix") (NASDAQ: PULM) have formed a collaboration to develop novel inhaled therapeutics to treat serious pulmonary diseases. The agreement provides Capsugel...
-
Feb 1, 2016
Pulmatrix, Inc. (NASDAQ: PULM) reports that enrollment is underway in the Company's European pilot bioequivalence study of PUR0200, a proprietary iSPERSE™ (Inhaled Small Particles Easily...
-
Jan 7, 2016
Pulmatrix, Inc., (NASDAQ: PULM) will present a business update at Biotech Showcase 2016 on Monday, January 11th at 2:30 pm PST (5:30 pm EST). A live webcast of the presentation may be accessed in...
-
Dec 22, 2015
What: Pulmatrix, Inc. (Nasdaq: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...
-
Dec 18, 2015
Pulmatrix, Inc. (Nasdaq: PULM) announced that the Company's common stock has qualified for and will begin trading today on the Nasdaq Global Market. The trading symbol remains PULM. Prior to...
-
Dec 8, 2015
Pulmatrix, Inc. (NASDAQ: PULM), a biopharmaceutical company developing inhaled therapies for pulmonary disease, today announced the appointment of Mark Iwicki as chairman of its board of...
-
Nov 12, 2015
Pulmatrix, Inc. (NASDAQ: PULM) reports third quarter financial results and provides an update on the progress year to date on the business and its drug development pipeline. Since the beginning of...
- Oct 9, 2015
Pulmatrix, Inc., (NASDAQ: PULM) will be webcasting the Company's investor presentation at two upcoming investor conferences. Pulmatrix will be presenting at the Dawson James 2015 Small Cap Growth...
-
Oct 8, 2015Data to be Presented at 2015 North American Cystic Fibrosis Conference
Pulmatrix, Inc. (NASDAQ: PULM) today announced preclinical data showing that PUR1900 (iSPERSE™-formulated itraconazole), which is being developed as the first inhaled antifungal medication for...
